Evaluation of CD8+ response in QuantiFERON-TB Gold Plus as a marker of recent infection - 18/08/21
, Clara Morais b, Sofia Santos b, Ricardo Reis bAbstract |
Background |
Diagnosis and treatment of latent tuberculosis (TB) infection (LTBI) is essential for the elimination of TB. Preventive therapy could be limited to those with recent TB contact. QuantiFERON-TB Gold Plus (QFT-Plus), a new Interferon-γ release assay, includes a new antigen tube (TB2), which elicits CD4+ and CD8+ T-cell responses.
Objective |
The aim of the study was to evaluate CD8+ T-cell response as a marker of recent TB infection.
Design |
We retrospectively studied 1165 patients who were screened for LTBI. Patients were divided according to history of recent exposure to TB (contact with a confirmed index case in the previous year). CD8+ T-cell activity was measured as the difference between QFT-Plus tubes (TB2-TB1) using two cut-offs (>0.35 IU/mL and >0.60 IU/mL).
Results |
CD8+ T-cell activity was significantly higher in the exposed group for both cut-offs (96 - 13% vs 36 - 5% patients - OR 1.68, 95% CI 1.13–2.52 for >0.35 IU/mL and 77 vs 28 patients - OR 1.72 95% CI 1.10–2.70 for >0.60 IU/mL).
CD8+ T-cell activity also showed an association with positive sputum smear of the index case and higher exposure time.
Conclusion |
CD8+ T-cell activity as measured with TB2-TB1 shows a significant association with recent exposure to TB, especially in patients with higher exposure and may prove to be a useful tool in identifying patients with recent LTBI.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Diagnosis and treatment of latent Tuberculosis infection is essential. |
• | QuantiFERON-TB Gold Plus provides surrogate markers of CD8+ T-cell responses. |
• | CD8+T-cell activity was associated with being a recent contact. |
• | CD8+T-cell IFNγ response was associated with smear grade of index and estimated exposure time. |
Keywords : Latent tuberculosis infection, Interferon-γ release assay, QuantiFERON-TB Gold plus
Plan
Vol 185
Article 106508- août 2021 Retour au numéro
Article précédent
- Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial
- Mohammadamin Sadeghdoust, Majid Mirsadraee, Farnaz Aligolighasemabadi, Mohammad Reza Khakzad, Amirhossein Hashemi Attar, Saeed Naghibi
- Predictors of failure of high flow nasal cannula failure in acute hypoxemic respiratory failure due to COVID-19
- Orlando Garner, Deepa Dongarwar, Hamisu M. Salihu, Jairo H. Barrantes Perez, Jocelyn Abraham, Cameron McBride, Sindhu Mathew, Preethi Antony, Keegan Collins, Katherine L. Richards, Christopher M. Howard
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?